IN2012DN03127A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03127A
IN2012DN03127A IN3127DEN2012A IN2012DN03127A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A IN 3127DEN2012 A IN3127DEN2012 A IN 3127DEN2012A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A
Authority
IN
India
Application number
Inventor
Zhanggui Wu
Original Assignee
Zhanggui Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhanggui Wu filed Critical Zhanggui Wu
Publication of IN2012DN03127A publication Critical patent/IN2012DN03127A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3127DEN2012 2009-09-18 2012-04-11 IN2012DN03127A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24354909P 2009-09-18 2009-09-18
PCT/US2010/049199 WO2011035077A1 (en) 2009-09-18 2010-09-17 Novel compounds and therapeutic use thereof for protein kinase inhibition

Publications (1)

Publication Number Publication Date
IN2012DN03127A true IN2012DN03127A (en) 2015-09-18

Family

ID=43759014

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3127DEN2012 IN2012DN03127A (en) 2009-09-18 2012-04-11

Country Status (12)

Country Link
US (2) US8815863B2 (en)
EP (2) EP2477496B1 (en)
JP (1) JP6155026B2 (en)
CN (2) CN102711475B (en)
AU (2) AU2010295492B2 (en)
CA (1) CA2774367C (en)
ES (2) ES2587509T3 (en)
IN (1) IN2012DN03127A (en)
MX (1) MX2012003286A (en)
NZ (1) NZ599453A (en)
RU (1) RU2012109220A (en)
WO (1) WO2011035077A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2587509T3 (en) * 2009-09-18 2016-10-25 Zhanggui Wu Thieno [2,3-d] pyridazine derivatives and therapeutic use thereof for protein kinase inhibition
CN112472699A (en) 2013-07-26 2021-03-12 种族肿瘤学公司 Combination methods for improving the therapeutic benefit of bisantrene and derivatives
CN115038439B (en) * 2020-01-07 2026-04-21 上海华禹生物科技有限公司 Cancer combination therapy using CHK inhibitors
WO2021177728A1 (en) * 2020-03-04 2021-09-10 (주)파로스아이바이오 Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer
EP4137494A4 (en) * 2020-04-17 2024-03-13 ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Crystal form of thiofuran pyridazine compound, preparation method therefor and application thereof
CN116332960A (en) * 2021-12-23 2023-06-27 上海优理惠生医药有限公司 A kind of pyridazine compound, its pharmaceutical composition and application
CN117263950A (en) * 2022-06-13 2023-12-22 上海优理惠生医药有限公司 A kind of pyridazine compound, its pharmaceutical composition and application
JP2024026975A (en) * 2022-08-16 2024-02-29 富士フイルム株式会社 Syk inhibitors and pharmaceutical compositions
CN117003736B (en) * 2023-10-07 2023-12-15 天津匠新致成科技有限公司 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
ATE501138T1 (en) * 2004-01-05 2011-03-15 Astrazeneca Ab THIOPHENE DERIVATIVES AS CHK-1 INHIBITORS
CA2563990A1 (en) 2004-05-04 2005-11-10 Sharada Shenvi Labadie Thienopyridazines as ikk inhibitors
AU2005238180A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridines as IKK inhibitors
CN101189243A (en) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 Substituted heterocycles and their use as inhibitors of CHK1, PDK1 and PAK
EP1869052A1 (en) * 2005-04-06 2007-12-26 AstraZeneca AB Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007124181A2 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
KR20090027754A (en) 2006-07-03 2009-03-17 코닌클리케 필립스 일렉트로닉스 엔.브이. Beverage Dispenser with Freshness Indicator
CN101481380B (en) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof
ES2587509T3 (en) * 2009-09-18 2016-10-25 Zhanggui Wu Thieno [2,3-d] pyridazine derivatives and therapeutic use thereof for protein kinase inhibition

Also Published As

Publication number Publication date
CA2774367A1 (en) 2011-03-24
US20120232082A1 (en) 2012-09-13
CN104628741A (en) 2015-05-20
EP2477496A4 (en) 2013-02-27
US9487539B2 (en) 2016-11-08
AU2010295492B2 (en) 2016-05-05
AU2010295492A1 (en) 2012-05-03
AU2016204867B2 (en) 2017-02-16
BR112012006062A2 (en) 2015-09-08
ES2481791T3 (en) 2014-07-31
HK1170908A1 (en) 2013-03-15
CN102711475A (en) 2012-10-03
AU2016204867A1 (en) 2016-07-28
RU2012109220A (en) 2013-10-27
EP2826780A1 (en) 2015-01-21
JP2013505254A (en) 2013-02-14
EP2826780B1 (en) 2016-06-01
ES2587509T3 (en) 2016-10-25
US8815863B2 (en) 2014-08-26
US20150072987A1 (en) 2015-03-12
WO2011035077A1 (en) 2011-03-24
CN102711475B (en) 2015-01-28
EP2477496B1 (en) 2014-04-16
CA2774367C (en) 2018-07-10
NZ599453A (en) 2014-03-28
JP6155026B2 (en) 2017-06-28
EP2477496A1 (en) 2012-07-25
MX2012003286A (en) 2012-06-19

Similar Documents

Publication Publication Date Title
BE2015C040I2 (en)
BRPI0925311A2 (en)
BRPI0924307A2 (en)
BRPI1009599A2 (en)
BR112012012396A2 (en)
BR122021004633A2 (en)
BR112012000665A2 (en)
BR112012012487A2 (en)
BR122017024704A2 (en)
BR112012003853A2 (en)
BR112012012080A2 (en)
BRPI0924534A2 (en)
BR112012001263A2 (en)
BR122019005883A2 (en)
BRPI1004942A2 (en)
BR112012014856A2 (en)
BR112012000159A2 (en)
BR112012002627A2 (en)
BR112012000255A2 (en)
BR112012005951A2 (en)
BR112012000156A2 (en)
BR122017013721A2 (en)
BRPI0925022A2 (en)
BRPI0924617A2 (en)
BR112012016234A2 (en)